Clinical trials: Anti-CD30
Large Cell Lymphoma
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
- Trial name
- NCT00099255
- Testing
- SGN-30
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Seagen Inc.
Relapsed/Refractory Lymphoma
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
This study is an exploratory clinical trial of a single-center, open-label, single-dose treatment of anti-CD20/CD30-CAR-T cells in subjects with relapsed/refractory lymphoma.
- Trial name
- NCT06532643
- Testing
- anti-CD20/CD30-CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai First Song Biotechnology Co., LTD
Hodgkin Lymphoma, NK/T Cell Lymphoma
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.
- Conditions
- Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05208853
- Testing
- Anti CD30 CAR-T Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific…
- Conditions
- Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
- Trial name
- NCT05544968
- Testing
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical College of Wisconsin
Anti-CD30, Brentuximab
Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
This study will be held in the clinical oncology department, Helwan University, and Police Hospital, aiming to compare the efficacy and safety of anti-CD30 (BV) + Doxorubicin, Vinblastine, and Dacarbazine (AVD) versus the…
- Conditions
- Anti-CD30, Brentuximab, Doxorubicin, Vinblastine
- Trial name
- NCT07171827
- Testing
- Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine, Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Helwan University
Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.
- Conditions
- Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, NK/T-cell Lymphoma
- Trial name
- NCT04008394
- Testing
- Anti-CD30 CAR T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
B Cell Malignancies
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
This study is a single-center,open-label,single-dose clinical trial of anti-CD20/CD30-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after lymphocyte depletion pre-treatment.
- Trial name
- NCT06519344
- Testing
- anti-CD20/CD30-CAR-T Cells
- Volunteers
- 12 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of…
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00337194
- Testing
- monoclonal antibody SGN-30, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed.
- Conditions
- Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell
- Trial name
- NCT03049449
- Testing
- Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large-Cell Lymphoma
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL).
- Trial name
- NCT00079755
- Testing
- SGN-30 (anti-CD30 mAb)
- Where
- 18 sites in United States
- Volunteers
- 80 people
- Sponsor
- Seagen Inc.